Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY P HOWELL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1821058710
CMS profile
82008
Location
HAGERSTOWN, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,386.39

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,386.39 78

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY P HOWELL

NPI 1821058710 · CMS profile ID 82008

Allopathic & Osteopathic Physicians / Internal Medicine

HAGERSTOWN, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821058710?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY P HOWELL, NPI 1821058710, CMS profile ID 82008. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821058710?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MARY P HOWELL, NPI 1821058710, CMS profile ID 82008. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821058710?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MARY P HOWELL, NPI 1821058710, CMS profile ID 82008, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1821058710?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $1,386.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $21.3804/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727793413 CMS
E.R. Squibb & Sons, L.L.C. $0.2104/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727793417 CMS
Flexion Therapeutics, Inc. $19.3404/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752740351 CMS
Hikma Pharmaceuticals USA $14.3804/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 729268127 CMS
Horizon Therapeutics plc $11.8303/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721404579 CMS
Mallinckrodt Hospital Products Inc. $14.9503/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751702009 CMS
Amgen Inc. $23.9003/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741218127 CMS
Janssen Biotech, Inc. $22.4203/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719292711 CMS
Amgen Inc. $18.8103/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741218123 CMS
UCB, Inc. $14.5903/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746079469 CMS
FIDIA PHARMA USA INC. $9.3503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748295841 CMS
AbbVie Inc. $23.8002/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721885637 CMS
Janssen Biotech, Inc. $18.3402/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719292713 CMS
Janssen Biotech, Inc. $20.9602/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719292707 CMS
UCB, Inc. $17.0902/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746078683 CMS
Novartis Pharmaceuticals Corporation $18.4402/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725814921 CMS
AbbVie Inc. $16.2402/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721885625 CMS
AbbVie Inc. $1.7002/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721885629 CMS
AbbVie Inc. $0.8002/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721885633 CMS
Mallinckrodt Hospital Products Inc. $16.5602/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751702007 CMS
E.R. Squibb & Sons, L.L.C. $17.0902/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727793399 CMS
Mallinckrodt Hospital Products Inc. $17.2102/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751702005 CMS
Mallinckrodt Hospital Products Inc. $1.3602/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751702003 CMS
Amgen Inc. $25.3001/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741417273 CMS
Janssen Biotech, Inc. $1.5001/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719292705 CMS
UCB, Inc. $19.8801/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746111305 CMS
Novartis Pharmaceuticals Corporation $14.4201/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725814915 CMS
Radius Health, Inc. $16.4401/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746305023 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,614.98 88
PY2020 $1,386.39 78
PY2021 $940.60 58
PY2022 $1,065.88 46
PY2023 $1,327.81 57
PY2024 $985.21 39
PY2025 $1,207.00 46

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,417,695.32 241
PY2024 Recipient $6,389.46 2
PY2024 Principal investigator $1,061,782.58 250
PY2023 Principal investigator $709,243.33 245
PY2022 Principal investigator $666,868.09 278
PY2021 Principal investigator $875,937.11 108
PY2020 Principal investigator $694,377.09 88
PY2019 Recipient $5,681.20 3
PY2019 Principal investigator $782,787.40 91

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

241 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $412.00 12/16/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228790
Principal investigator 1 Janssen Research & Development, LLC $52.00 12/16/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228922
Principal investigator 1 Janssen Research & Development, LLC $52.00 12/16/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229027
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 12/16/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,389.96 12/16/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289726
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,819.31 12/16/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289728
Principal investigator 1 Janssen Research & Development, LLC $3,140.00 12/15/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382209
Principal investigator 1 Janssen Research & Development, LLC $23.00 12/08/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228491
Principal investigator 1 Janssen Research & Development, LLC $23.00 12/08/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228617
Principal investigator 1 Janssen Research & Development, LLC $23.00 12/08/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228796
Principal investigator 1 Janssen Research & Development, LLC $23.00 12/08/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228804
Principal investigator 1 Janssen Research & Development, LLC $23.00 12/08/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229285
Principal investigator 1 Janssen Research & Development, LLC $23.00 12/08/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229486
Principal investigator 1 Janssen Research & Development, LLC $92.00 12/01/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382256
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $114.75 12/01/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $338.00 12/01/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288913
Principal investigator 1 Janssen Research & Development, LLC $412.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228316
Principal investigator 1 Janssen Research & Development, LLC $412.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228326
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228374
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228401
Principal investigator 1 Janssen Research & Development, LLC $412.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228678
Principal investigator 1 Janssen Research & Development, LLC $412.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228687
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228773
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228813
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228863
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229109
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229165
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229187
Principal investigator 1 Janssen Research & Development, LLC $52.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229203
Principal investigator 1 Janssen Research & Development, LLC $3,419.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229411
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229491
Principal investigator 1 Janssen Research & Development, LLC $2,010.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229509
Principal investigator 1 Janssen Research & Development, LLC $493.00 11/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229549
Principal investigator 1 Novartis Pharmaceuticals Corporation $40.45 11/10/2025 Non-covered Recipient Entity
OSTEOPOROSIS AND CLINICAL TRIAL CENTER
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190306511
Principal investigator 1 Janssen Research & Development, LLC $1,809.00 11/06/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382249
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 11/04/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287937
Principal investigator 1 Janssen Research & Development, LLC $5,532.00 11/03/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382176
Principal investigator 1 Janssen Research & Development, LLC $1,517.00 10/31/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382217
Principal investigator 1 Novartis Pharmaceuticals Corporation $148,485.51 10/08/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES, MD, PA
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190299355
Principal investigator 1 Janssen Research & Development, LLC $9,866.00 10/06/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382154
Principal investigator 1 UCB SA $1,543.00 09/24/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657936
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,935.41 09/16/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285462
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,326.23 09/02/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284699
Principal investigator 1 Janssen Research & Development, LLC $3,419.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228349
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228738
Principal investigator 1 Janssen Research & Development, LLC $52.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228906
Principal investigator 1 Janssen Research & Development, LLC $412.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228936
Principal investigator 1 Janssen Research & Development, LLC $52.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229072
Principal investigator 1 Janssen Research & Development, LLC $52.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229126
Principal investigator 1 Janssen Research & Development, LLC $52.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229242
Principal investigator 1 Janssen Research & Development, LLC $52.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229343
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229385
Principal investigator 1 Janssen Research & Development, LLC $493.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229403
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 08/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229518
Principal investigator 1 Janssen Research & Development, LLC $11,449.00 08/28/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382161
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,729.70 08/19/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES, MD, PA
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190299351
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,797.20 08/19/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES, MD, PA
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190299359
Principal investigator 1 Janssen Research & Development, LLC $2,643.00 08/11/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382262
Principal investigator 1 UCB SA $270.00 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659232
Principal investigator 1 UCB SA $33.75 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659234
Principal investigator 1 UCB SA $826.20 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659236
Principal investigator 1 UCB SA $74.25 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659244
Principal investigator 1 UCB SA $303.75 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659246
Principal investigator 1 UCB SA $90.45 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659248
Principal investigator 1 UCB SA $68.85 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659250
Principal investigator 1 UCB SA $39.15 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659252
Principal investigator 1 UCB SA $39.15 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659254
Principal investigator 1 UCB SA $39.15 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659256
Principal investigator 1 UCB SA $39.15 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659258
Principal investigator 1 UCB SA $226.80 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659260
Principal investigator 1 UCB SA $82.35 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659262
Principal investigator 1 UCB SA $75.60 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659264
Principal investigator 1 UCB SA $81.00 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659266
Principal investigator 1 UCB SA $74.25 08/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659268
Principal investigator 1 UCB SA $2,137.00 08/06/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659228
Principal investigator 1 UCB SA $297.00 08/06/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659230
Principal investigator 1 Janssen Research & Development, LLC $13,467.00 07/31/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382185
Principal investigator 1 Genentech, Inc. $3,287.00 07/29/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PC STEVEN J KLEIN
Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211620069
Principal investigator 1 Janssen Research & Development, LLC $52.00 07/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228354
Principal investigator 1 Janssen Research & Development, LLC $23.00 07/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228512
Principal investigator 1 Janssen Research & Development, LLC $23.00 07/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228560
Principal investigator 1 Janssen Research & Development, LLC $104.00 07/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229158
Principal investigator 1 Janssen Research & Development, LLC $23.00 07/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229524
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,825.64 07/17/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282786
Principal investigator 1 Janssen Research & Development, LLC $16,065.00 07/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382169
Principal investigator 1 Janssen Research & Development, LLC $2,136.00 07/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382242
Principal investigator 1 Janssen Research & Development, LLC $52.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228462
Principal investigator 1 Janssen Research & Development, LLC $412.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228631
Principal investigator 1 Janssen Research & Development, LLC $2,010.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228637
Principal investigator 1 Janssen Research & Development, LLC $52.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228645
Principal investigator 1 Janssen Research & Development, LLC $52.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229004
Principal investigator 1 Janssen Research & Development, LLC $412.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229079
Principal investigator 1 Janssen Research & Development, LLC $412.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229292
Principal investigator 1 Janssen Research & Development, LLC $52.00 06/30/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229314
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,344.79 06/24/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223281800
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,712.00 06/11/2025 Non-covered Recipient Entity
Klein And Associates, Md, Pa
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235996309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,117.66 06/10/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280984
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228299
Principal investigator 1 Janssen Research & Development, LLC $412.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228385
Principal investigator 1 Janssen Research & Development, LLC $3,419.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228392
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228431
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228457
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228586
Principal investigator 1 Janssen Research & Development, LLC $412.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228652
Principal investigator 1 Janssen Research & Development, LLC $493.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228712
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228727
Principal investigator 1 Janssen Research & Development, LLC $412.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228846
Principal investigator 1 Janssen Research & Development, LLC $412.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228896
Principal investigator 1 Janssen Research & Development, LLC $412.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228944
Principal investigator 1 Janssen Research & Development, LLC $3,037.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229035
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229043
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229049
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229099
Principal investigator 1 Janssen Research & Development, LLC $493.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229116
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229378
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229416
Principal investigator 1 Janssen Research & Development, LLC $52.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229581
Principal investigator 1 Janssen Research & Development, LLC $2,107.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229596
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 05/28/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229604
Principal investigator 1 Janssen Research & Development, LLC $7,547.00 05/26/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382284
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,927.74 05/20/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279960
Principal investigator 1 Janssen Research & Development, LLC $1,079.17 05/19/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382193
Principal investigator 1 Janssen Research & Development, LLC $1,603.33 05/15/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382138
Principal investigator 1 Janssen Research & Development, LLC $5,875.00 05/15/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175382273
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228473
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228553
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228660
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228766
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228836
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228870
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228888
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228995
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229066
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229171
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229194
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229259
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229299
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229306
Principal investigator 1 Janssen Research & Development, LLC $366.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229475
Principal investigator 1 Janssen Research & Development, LLC $127.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229531
Principal investigator 1 Janssen Research & Development, LLC $23.00 05/07/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229566
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,060.00 05/01/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278758
Principal investigator 1 Janssen Research & Development, LLC $2,130.00 04/28/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382227
Principal investigator 1 UCB SA $297.00 04/25/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659430
Principal investigator 1 UCB SA $297.00 04/25/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246659432
Principal investigator 1 Janssen Research & Development, LLC $473.00 04/11/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382201
Principal investigator 1 UCB SA $194.01 04/07/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659438
Principal investigator 1 Janssen Research & Development, LLC $753.00 03/31/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382145
Principal investigator 1 UCB SA $297.00 03/26/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657678
Principal investigator 1 UCB SA $8,689.85 03/26/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657680
Principal investigator 1 UCB SA $1,161.00 03/26/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657682
Principal investigator 1 UCB SA $297.00 03/26/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF STUDY PARTICIPANTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS, ANKYLOSING SPONDYLITIS, AND NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 1246657684
Principal investigator 1 Janssen Research & Development, LLC $237.50 03/19/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229012
Principal investigator 1 UCB SA $857.50 03/17/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246656392
Principal investigator 1 Eli Lilly and Company $13,370.00 03/03/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883974
Principal investigator 1 Janssen Research & Development, LLC $4,872.00 03/03/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175382235
Principal investigator 1 UCB SA $1,316.39 02/28/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES, M.D. P.A.
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658392
Principal investigator 1 Janssen Research & Development, LLC $2,010.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228340
Principal investigator 1 Janssen Research & Development, LLC $493.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228519
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228539
Principal investigator 1 Janssen Research & Development, LLC $3,351.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228625
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228670
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228702
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228745
Principal investigator 1 Janssen Research & Development, LLC $412.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228756
Principal investigator 1 Janssen Research & Development, LLC $2,010.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228854
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228929
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228963
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229147
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229229
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229276
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229350
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229363
Principal investigator 1 Janssen Research & Development, LLC $412.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229372
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229394
Principal investigator 1 Janssen Research & Development, LLC $52.00 02/27/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229588
Principal investigator 1 Janssen Research & Development, LLC $875.00 02/24/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229424
Principal investigator 1 UCB SA $59,233.55 02/20/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659056
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,229.43 02/05/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES, MD, PA
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190308184
Principal investigator 1 Eli Lilly and Company $4,463.19 01/27/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187886248
Principal investigator 1 Novartis Pharmaceuticals Corporation $496,059.78 01/27/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES, MD, PA
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190308182
Principal investigator 1 Eli Lilly and Company $67,228.00 01/21/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES MD PA
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187885990
Principal investigator 1 UCB SA $12,139.40 01/20/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658292
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228423
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228497
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228525
Principal investigator 1 Janssen Research & Development, LLC $366.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228594
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228695
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228720
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228820
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229178
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229237
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229357
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229500
Principal investigator 1 Janssen Research & Development, LLC $23.00 01/17/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229557
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228291
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228307
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228335
Principal investigator 1 Janssen Research & Development, LLC $2,456.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228363
Principal investigator 1 Janssen Research & Development, LLC $493.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228370
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228409
Principal investigator 1 Janssen Research & Development, LLC $2,341.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228416
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228438
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228449
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228482
Principal investigator 1 Janssen Research & Development, LLC $493.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228505
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228534
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228570
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228576
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228600
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228608
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228781
Principal investigator 1 Janssen Research & Development, LLC $3,419.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228829
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228880
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228914
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228949
Principal investigator 1 Janssen Research & Development, LLC $2,144.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228957
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228973
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228980
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175228989
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229022
Principal investigator 1 Janssen Research & Development, LLC $3,419.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229058
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229088
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229136
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229214
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229222
Principal investigator 1 Janssen Research & Development, LLC $2,869.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229251
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229269
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229325
Principal investigator 1 Janssen Research & Development, LLC $493.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229331
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229432
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229440
Principal investigator 1 Janssen Research & Development, LLC $2,010.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229446
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229461
Principal investigator 1 Janssen Research & Development, LLC $52.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229468
Principal investigator 1 Janssen Research & Development, LLC $3,519.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229540
Principal investigator 1 Janssen Research & Development, LLC $412.00 01/13/2025 Non-covered Recipient Entity
Klein and Associates MD Pa
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175229572
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,424.00 01/08/2025 Non-covered Recipient Entity
Klein And Associates, Md, Pa
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1235996307
Principal investigator 1 Novartis Pharmaceuticals Corporation $95,473.36 01/07/2025 Non-covered Recipient Entity
KLEIN AND ASSOCIATES, MD, PA
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190308178
Principal investigator 1 UCB SA $2,700.00 01/02/2025 Non-covered Recipient Entity
KLEIN & ASSOCIATES MD PA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657300
Principal investigator 1 Novartis Pharmaceuticals Corporation $203,389.66 01/01/2025 Non-covered Recipient Entity
OSTEOPOROSIS AND CLINICAL TRIAL CENTER
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190306513